Evidence map›Paper›PMID 41624770›Full record

ArticleFrontiers in molecular biosciences2025

The predictive role of protease-activated receptor (PAR-1) polymorphisms and activated microplatelets on the severity of atherosclerosis - preliminary studies.

Urszula Jakobsche-Policht, Agnieszka Bronowicka-Szydełko, Rajmund Adamiec, Dorota Bednarska-Chabowska, Łukasz Lewandowski, Rafał Małecki, Kinga Gostomska-Pampuch, Joanna Adamiec-Mroczek, Marta Myszka-Kozłowska, Dagmara Baczyńska and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Urszula Jakobsche-PolichtDepartment of Angiology and Internal Diseases, Institute of Internal Diseases, Wroclaw Medical University, Wroclaw, Poland.
Agnieszka Bronowicka-SzydełkoDepartment of Biochemistry and Immunochemistry, Wroclaw Medical University, Wroclaw, Poland.
Rajmund AdamiecClinical Department of Diabetology, Hypertension and Internal Diseases, Institute of Internal Diseases, Wroclaw Medical University, Wroclaw, Poland.
Dorota Bednarska-ChabowskaClinical Department of Diabetology, Hypertension and Internal Diseases, Institute of Internal Diseases, Wroclaw Medical University, Wroclaw, Poland.
Łukasz LewandowskiDepartment of Biochemistry and Immunochemistry, Wroclaw Medical University, Wroclaw, Poland.
Rafał MałeckiDepartment of Non-Procedural Clinical Sciences, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland.
Kinga Gostomska-PampuchDepartment of Biochemistry and Immunochemistry, Wroclaw Medical University, Wroclaw, Poland.
Joanna Adamiec-MroczekClinical Department of Ophthalmology, Wroclaw Medical University, Wroclaw, Poland.
Marta Myszka-KozłowskaDepartment of Pediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Medical University, Wroclaw, Poland.
Dagmara BaczyńskaDepartment of Molecular and Cellular Biology Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland.
Maciej RabczyńskiClinical Department of Diabetology, Hypertension and Internal Diseases, Institute of Internal Diseases, Wroclaw Medical University, Wroclaw, Poland.
Edwin KuźnikClinical Department of Diabetology, Hypertension and Internal Diseases, Institute of Internal Diseases, Wroclaw Medical University, Wroclaw, Poland.
Jacek PolańskiClinical Department of Diabetology, Hypertension and Internal Diseases, Institute of Internal Diseases, Wroclaw Medical University, Wroclaw, Poland.
Helena MartynowiczClinical Department of Diabetology, Hypertension and Internal Diseases, Institute of Internal Diseases, Wroclaw Medical University, Wroclaw, Poland.
Daria DolińskaFaculty of Medicine, Wroclaw Medical University, Wroclaw Medical University, Wroclaw, Poland.
Paulina MatlakFaculty of Medicine, Wroclaw Medical University, Wroclaw Medical University, Wroclaw, Poland.
Julia SobczyńskaFaculty of Medicine, Wroclaw Medical University, Wroclaw Medical University, Wroclaw, Poland.
Maciej ZiomekFaculty of Medicine, Wroclaw Medical University, Wroclaw Medical University, Wroclaw, Poland.
Maciej TotaFaculty of Medicine, Wroclaw Medical University, Wroclaw Medical University, Wroclaw, Poland.
Wojciech StachFaculty of Medicine, Wroclaw Medical University, Wroclaw Medical University, Wroclaw, Poland.
Katarzyna MadziarskaClinical Department of Diabetology, Hypertension and Internal Diseases, Institute of Internal Diseases, Wroclaw Medical University, Wroclaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study is a comprehensive analysis of PAR-1 - involved in thrombin interaction with platelets (PLT), present on PLT and microparticles (PMP) - to understand its role in diabetic macroangiopathy (DM) and atherosclerosis obliterans (AO). The applied RT-PCR, aggregometry, flow cytometry, a proprietary method for PMP level determination, ELISA, and multidimensional statistical analysis allowed for the determination of: PAR-1 activation levels, its polymorphisms, PLT/PMP aggregation capacity, hemostatic factors, and their interrelationships. In DM, the -506D/D and IVS-14A/A polymorphisms were significantly more frequent, whereas the -506I/D was much more common in AO, suggesting the protective properties of the I allele and its potential significance as a prognostic factor for a milder course of atherosclerosis. Similarly, increased PMP activity in DM indicates that activated PMP contribute to the atherosclerosis progression. A probable explanation for the reduced PAR-1 activation in AO is its association with the observed lower levels of von Willebrand factor. Interaction analysis showed that although the percentage of PMP did not affect the odds of AO (among AO and DM), at high PMP percentages, increased PAR-1 activation became a factor elevating the AO odds. Quantitative assessment of PAR-1 and PMP allows for predicting the severity of atherosclerosis.

Indexed as

atherosclerosis obliteransdiabetic macroangiopathymicroplateletsplateletesprotease-activated receptor (PAR-1)

Identifiers

PMID41624770
PMCPMC12856924

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.